Payment overview · 2025
General Payments
$164.78
9 reported records · 8 companies
Healthcare provider profile · identity verified
David Glen Fielder, MD
Allopathic & Osteopathic Physicians|Family Medicine · BATESVILLE, AR · NPI 1821084377
Verified facts
What the public records show
CMS Open Payments records show David Glen Fielder, MD received $164.78 in general payments during 2025 across 9 reported records.
Abbott Laboratories accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.14 | 19.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.01 | 16.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.50 | 13.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.20 | 12.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.77 | 11.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.20 | 9.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.57 | 9.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.39 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $164.78 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $32.14 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.01 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 86 |
| Lisinopril | Lisinopril | 285 | 77 |
| Metformin Hcl | Metformin Hcl | 274 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 58 |
| Gabapentin | Gabapentin | 252 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 212 | 36 |
| Omeprazole | Omeprazole | 199 | 51 |
| Potassium Chloride | Potassium Chloride | 199 | 53 |
| Furosemide | Furosemide | 192 | 40 |
| Losartan Potassium | Losartan Potassium | 187 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 43 |
| Enalapril Maleate | Enalapril Maleate | 156 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 39 |
| Famotidine | Famotidine | 142 | 31 |
| Trazodone Hcl | Trazodone Hcl | 137 | 29 |
| Atenolol | Atenolol | 124 | 29 |
| Meloxicam | Meloxicam | 124 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 25 |
| Eliquis | Apixaban | 117 | 22 |
| Lorazepam | Lorazepam | 117 | 21 |
| Montelukast Sodium | Montelukast Sodium | 117 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 23 |
| Simvastatin | Simvastatin | 106 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 17 |
| Carvedilol | Carvedilol | 94 | 24 |
| Allopurinol | Allopurinol | 91 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 17 |
| Tramadol Hcl | Tramadol Hcl | 89 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 28 |
| Glimepiride | Glimepiride | 88 | 21 |
| Alendronate Sodium | Alendronate Sodium | 84 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 18 |
| Finasteride | Finasteride | 73 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 16 |
| Pregabalin | Pregabalin | 69 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 15 |
| Buspirone Hcl | Buspirone Hcl | 63 | 11 |
| Benazepril Hcl | Benazepril Hcl | 62 | 11 |
| Ezetimibe | Ezetimibe | 59 | 17 |
| Topiramate | Topiramate | 59 | suppressed |
| Alprazolam | Alprazolam | 58 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 15 |
| Jardiance | Empagliflozin | 54 | suppressed |
| Ramipril | Ramipril | 54 | 11 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 53 | 53 |
| Januvia | Sitagliptin Phosphate | 53 | 13 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Glipizide | Glipizide | 49 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 15 |
| Ozempic | Semaglutide | 45 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Naproxen | Naproxen | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Prednisone | Prednisone | 34 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 33 | suppressed |
| Sotalol | Sotalol Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 27 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | 11 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 23 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $164.78 · 9 records | Abbott Laboratories | CAPLYTA, FREESTYLE LIBRE 3, GEMTESA, LEQVIO, VOQUEZNA, VRAYLAR, XYOSTED, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error